Tomivosertib + Pembrolizumab + Pemetrexed
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer
Conditions
Non-small Cell Lung Cancer
Trial Timeline
Jun 2, 2021 → Dec 9, 2024
NCT ID
NCT04622007About Tomivosertib + Pembrolizumab + Pemetrexed
Tomivosertib + Pembrolizumab + Pemetrexed is a phase 2 stage product being developed by eFFECTOR Therapeutics for Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04622007. Target conditions include Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04622007 | Phase 2 | Active |
Competing Products
20 competing products in Non-small Cell Lung Cancer